This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
by Zacks Equity Research
Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma
Adaptimmune (ADAP) Down on End of Collaboration With Roche
by Zacks Equity Research
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
by Zacks Equity Research
The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $1.20, representing a -1.24% change from its previous close.
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
by Zacks Equity Research
Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
by Zacks Equity Research
Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Adaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.60, representing a +1.5% change from its previous close.
Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.55, representing a -1.79% change from its previous close.
Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Adaptimmune (ADAP) is expected to provide regulatory and developmental updates on its pipeline programs in its upcoming earnings release, given the absence of marketed products in its portfolio.
Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
by Zacks Equity Research
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
Buy 5 Top-Ranked Stocks With Rising P/E in July
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).
Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date
by Zacks Equity Research
Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
by Zacks Equity Research
Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.
Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug
by Zacks Equity Research
Liquidia (LQDA) signs an exclusive licensing agreement with Pharmosa to jointly develop and commercialize PAH and PH-ILD treatment candidate, L606, in North America. Shares of the company rise 11%.
Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7%
by Zacks Equity Research
Reata's (RETA) prior approval supplement application to update the drug substance specification for Skyclarys gets FDA's nod. Shares of the company gain 7% on Wednesday in response.
Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall
by Zacks Equity Research
Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.
AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval
by Zacks Equity Research
AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.
Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data
by Zacks Equity Research
Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.
Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal
by Zacks Equity Research
Horizon (HZNP) announces positive top-line results from its phase III study evaluating Tepezza for treating Thyroid Eye Disease with high disease activity in Japan.
uniQure (QURE) Falls on Mixed Huntington's Disease Study Results
by Zacks Equity Research
uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.
Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia
by Zacks Equity Research
Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
by Zacks Equity Research
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
GSK Announces Extension of FDA Review for Rare Blood Therapy
by Zacks Equity Research
GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study
by Zacks Equity Research
Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.